Preventive analgesia is defined as the persistence of the analgesic effects of a drug beyond the clinical activity of the drug. The N-methyl D-aspartate receptor plays a critical role in the sensitisation of pain pathways induced by injury. Nitrous oxide inhibits excitatory N-methyl D-aspartate sensitive glutamate receptors. The objective of our study was to test the efficacy of nitrous oxide as a preventive analgesic. We conducted a retrospective analysis of data from a subset of patients (n=100) randomly selected from a previous major multicentre randomised controlled trial on nitrous oxide (ENIGMA trial). Data analysed included postoperative analgesic requirements, pain scores and duration of patient-controlled analgesia during the first 72 postoperative hours. There was no significant difference in postoperative oral morphine equivalent usage (nitrous group 248 mg, no nitrous group 289 mg, mean difference -43 mg, 95% confidence interval 141 to 54 mg). However, patients who received nitrous oxide had a shorter duration of patient-controlled analgesia use (nitrous group 35 hours, no nitrous group 51 hours, mean difference -16 hours, 95% confidence interval -29 to -2 hours, P=0.022). There was no difference in pain scores between the groups. The shorter patient-controlled analgesia duration in the nitrous oxide group suggests that intraoperative nitrous oxide may have a preventive analgesic effect.
Tissue damage resulting from inflammation, trauma or surgery may lead to peripheral and central sensitisation leading to hyperalgesia, allodynia or persistent pain [1] [2] [3] [4] [5] . Preventive analgesia is a clinical concept where an analgesic drug given in the perioperative period leads to a reduction in central sensitisation with reduced pain, analgesia use or both at a later time [6] [7] [8] .
The N-methyl D-aspartate (NMDA) receptor is believed to play a critical role in sensitisation induced by surgical injury [1] [2] [3] [4] [5] . The analgesic effects of nitrous oxide are mediated via a number of receptor types [9] [10] [11] [12] , but inhibition of excitatory NMDAmediated glutamate receptors is believed to be a key mechanism 13 . Nitrous oxide has been used for many decades for its analgesic, anaesthetic and anxiolytic properties 11, 14, 15 . Richebe et al have shown that low concentrations of nitrous oxide (20 to 50%) significantly reduced surgical and opioid-induced hyperalgesia in an animal model 5 .
In order to investigate further the potential preventive analgesic effects of nitrous oxide after major surgery, we retrospectively analysed data from a random sample of patients previously enrolled in a major multicentre randomised controlled trial on nitrous oxide (ENIGMA trial) 14 .
METHOD
We conducted a retrospective analysis of data from a sample of patients drawn from the ENIGMA trial 14 , a prospective randomised double blind parallel group effectiveness study 14 conducted between April 2003 and November 2004. The ENIGMA trial evaluated whether the use of nitrous oxide during general anaesthesia for major surgery increases the duration of hospital length of stay, intensive care length of stay or postoperative complications 14 .
Ethics approval and informed consent were obtained for the ENIGMA trial and further analysis of patient data was approved under the initial ENIGMA trial ethics approval. Patients eligible for this trial were aged 18 years or older, scheduled to undergo general anaesthesia for surgery that included a skin incision and expected to exceed two hours duration, with an inpatient admission for more than three days. Patients were excluded if undergoing cardiac surgery or thoracic surgery requiring onelung ventilation, or if the anaesthetist considered that nitrous oxide was contraindicated 14 . Patients were also excluded from our analysis if they required continued intubation in the intensive care unit, received regional neural blockade or had a history of opioid tolerance.
After approval from the chief investigator, patients' medical records were obtained and analysed for postoperative opioid requirements, adjunct analgesic requirements, pain intensity scores by numerical rating scale and duration of patientcontrolled analgesia (PCA) during the first 72 hours postoperatively. A random number generation program randomly selected 100 of the 265 patients enrolled in the ENIGMA trial from our institution.
Sample size was calculated to detect a 30% or greater difference in opioid equivalent use (using an alpha error 0.05 and a beta error 0.20) for a mean of 100 mg and standard deviation of 50.
The primary endpoint was opioid requirements in the first 72 postoperative hours. This time frame was chosen to best enable accurate data collection in relation to acute pain. Secondary endpoints included duration of PCA infusion and pain intensity rating using the numerical rating scale.
All data for this study were collected by the authors, who were blinded to the nature of the anaesthetic. Data were collected from patient medical records and included all relevant drug charts and perioperative records, excluding anaesthetic charts. Other relevant information from the ENIGMA trial data was made available to the investigators.
Data were recorded on a case report form. The data included PCA drug, dose and duration, adjunctive analgesics and pain intensity scores in the recovery room and for 72 hours postoperatively. Conversion of dosage for opioids other than morphine ('oral morphine equivalents') was calculated using a validated scale 16 . Oral morphine equivalent data was not normally distributed. The data was analysed using a Mann-Whitney u test. Patient controlled analgesia duration and pain score data were compared using Student's t-test.
RESuLTS
The two groups had comparable demographics, comorbidities and type of surgery (Table 1) . Table 2 displays the oral morphine equivalents and PCA duration postoperatively for patients receiving an anaesthetic with or without nitrous oxide. There was a lower oral morphine equivalent requirement for the nitrous oxide group, but this was not statistically significant (mean reduction 43 mg, P=0.38). The nitrous group did have a 16 hour shorter duration of PCA use (P=0.022). Table 3 shows pain scores over this same period. The pain scores showed no significant difference between the two groups.
DISCuSSIoN
We found a statistically significant shorter duration of PCA use in the nitrous oxide group. This suggests that intraoperative nitrous oxide may have a preventive analgesic effect. There was also a 13% lower postoperative morphine requirement in the nitrous oxide group, although this was not statistically different from the non-nitrous group.
Pain is of major concern for patients and their carers, with up to 80% of patients reporting pain postoperatively 17, 18 . This has major implications for the healthcare system. For patients, this may include a susceptibility to the development of chronic pain 19 , exposure to side-effects of analgesic medications, in particular opioids, and fear of further surgery [17] [18] [19] . High opioid consumption is associated with doserelated adverse effects, which may contribute to delayed postoperative recovery 19, 21 . The burden to the healthcare system of inadequately managed pain includes the direct costs of treatment, increased length of stay 20 and loss of productivity after discharge.
Preventive analgesia refers to analgesia given in the perioperative period that has the potential to reduce central sensitisation. This may reduce subsequent pain as well as analgesic requirements 7, 8, 22 . Preventive analgesia may minimise opioid use in the acute postoperative period and may also improve quality of recovery after surgery and have a positive bearing on physical and psychological outcome for patients.
Stimulation of the NMDA receptor is believed to play a critical role in sensitisation of pain pathways induced by surgical stimulus resulting in persistent pain [1] [2] [3] [4] [5] . Several studies have evaluated the use of NMDA antagonists (ketamine, magnesium, dextromethorphan) used preventively to reduce central sensitisation 5, 8, 23, 24 . Animal studies have suggested that even at low concentrations (20 to 40%), nitrous oxide may lead to decreased opioid, inflammatory and surgically-induced hyperalgesia 5 . Therefore, intraoperative low-dose nitrous oxide may serve as a preventive analgesic. This may relate to its mechanism of action as a NMDA receptor antagonist.
A large retrospective study has shown an association between nitrous oxide use and increased postoperative pain in need of intervention in the post-anaesthetic care unit 25 . However, there were several potential sources of bias in this study. The study populations were not randomised and only 10% of subjects received nitrous oxide. It was not reported why these patients received nitrous oxide as part of their anaesthetic. Thus, those receiving nitrous oxide may have had more extensive surgery, less analgesia or both. Additionally, the study did not collect data for the period outside the postanaesthetic care unit (i.e. 72 hours postoperatively).
We found no statistical difference in postoperative opioid requirements or pain scores over the first 72 hours postoperatively. This may indicate the amount or duration of exposure to nitrous oxide was inadequate to provide a statistically or clinically significant analgesic effect during the postoperative period. It may also indicate that nitrous oxide is not a preventive analgesic. The study may also have had inadequate power to detect clinically relevant differences. Therefore, our findings would need to be investigated further in a larger randomised controlled trial.
A shortened duration of PCA use in the patients who received a nitrous oxide based anaesthetic may indicate a decreased intensity of pain and a possible reduction in postoperative hyperalgesia. There are a number of factors that determine the duration of PCA use, but these factors would be unlikely to affect one group more than the other.
Shortening the PCA duration may have positive effects for the patient and healthcare system. Shorter PCA duration allows earlier mobilisation, earlier removal of intravenous access, improved patient autonomy and comfort. Such patients may have an increased likelihood of earlier discharge 20 , although the ENIGMA trial did not show a decreased length of hospital stay overall. For the healthcare system, there could be the cost benefit of early discharge and the shorter involvement of pain services in patient management.
Preventive analgesia is the product of many interacting patient, anaesthetic, medical and surgical factors. Factors including individual patient differences in pain processing, variations in anaesthetic technique, adjuvant medications and site, extent and duration of surgery may increase the risk of developing hyperalgesic syndromes 24 . We demonstrated that nitrous oxide decreases PCA duration in the first 72 hours postoperatively that may indicate a clinically relevant preventive analgesic effect.
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